Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.

by Dennie T Frederick, Roberto A Salas Fragomeni, Aislyn Schalck, Isabel Ferreiro-Neira, Taylor Hoff, Zachary A Cooper, Rizwan Haq, David J Panka, Lawrence N Kwong, Michael A Davies, James C Cusack, Keith T Flaherty, David E Fisher, James W Mier, Jennifer A Wargo, Ryan J Sullivan
Published 2014-01-01